skip to main content

    Updated Visitor Guidelines

 

MENU

 

Cancer Scientists of the Future

At the U-M Rogel Cancer Center, researchers believe that stronger lines of communication between cancer disciplines are one important way to expedite the translation of research discoveries into the clinic.

Technologies Developed by the Rogel Cancer Center Offer Promise for Early Detection, and Better Monitoring and Management of Cancer

Improvement and advancements in molecular imaging, biopsy alternatives and implantable devices are underway at the U-M Rogel Cancer Center. The goal is improving detection, diagnosis and treatment of cancers.

Better Communication, Better Cancer Care

Every day, University of Michigan Rogel Cancer Center researchers are developing new ways to treat cancer. Genetic testing to identify those at risk. Next-generation imaging to see it. Precision therapies to target it. They’re also working on new ways to talk about it.

Genetic Data Impacts Clinical Cancer Care

As genetic testing of tumor tissue becomes more common among patients recently diagnosed with cancer and moves closer to standard of care for identifying certain types of alterations, these genetic data are being systematically collected and analyzed by researchers.

How U-M Researchers are Using Big Data to Transform Cancer Care

Physicians and researchers, including those at the University of Michigan Rogel Cancer Center, are tapping into the wealth of previously inaccessible information in patients’ individual cancers and bringing that data together to help improve care for millions. The umbrella term from this work has come to be known as big data.

What Makes U-M one of the Premier Academic Cancer Drug Development Programs in the Country

When Kelly Sexton, Ph.D., Associate Vice President for Research, Technology Transfer and Innovation Partnerships, meets with investors and executives, they’re surprised to learn that the University of Michigan has the largest annual research volume of any public university in the country -- over $1.6 billion -- and that Michigan is No. 2 in the country for research funding from the National Institutes of Health. This very solid foundation allows cancer research to flourish -- with nearly 50 anti-cancer drug-development projects currently underway.

Harnessing the Immune System to Target Cancer

When Weiping Zou, M.D., PH.D., Charles B. De Nancrede Professor of Surgery, Immunology, Biology and Pathology at the University of Michigan, first started looking at cancer immunology, he was one of only a handful in the field who believed in the idea. Today, immunotherapy has revolutionized cancer treatment and become one of the most promising avenues in cancer research.

U-M Research Into Stem Cell Development May Lead to Anti-Cancer Treatments

By studying two proteins, WDR5 and p53, researchers hoped to learn how -- or if -- these proteins could influence what stem cells developed into. WDR5 and p53 have long been studied in relation to cancer and this research also shed light on how WDR5 regulates p53 both directly and indirectly. For this reason, the research may also help illuminate an emerging class of anti-cancer drugs, WDR5 inhibitors.

Monitoring Body Temperature Could Provide Early Warning for Graft-Versus-Host-Disease

By continuously monitoring the body temperature of mice that had undergone bone-marrow transplants, researchers were able to detect early warning signs of graft-versus-host disease -- a dangerous, sometimes deadly response of the transplanted immune system -- in a simple, non-invasive way.

Rogel Cancer Center names new associate directors for data and population sciences

The University of Michigan Rogel Cancer has named Bhramar Mukherjee, Ph.D., associate director for quantitative data sciences, and Christopher Friese, Ph.D., R.N., associate director for cancer control and population sciences.

Pages